<p>Shun Lu joins Ben Abbott of The Lancet to discuss the phase 3 HARMONi-6 trial of ivonescimab plus chemotherapy as first-line treatment in advanced squamous non-small-cell lung cancer, which is being presented at ESMO 2025.</p>

Shun Lu joins Ben Abbott of The Lancet to discuss the phase 3 HARMONi-6 trial of ivonescimab plus chemotherapy as first-line treatment in advanced squamous non-small-cell lung cancer, which is being presented at ESMO 2025.

In conversation with... Shun Lu

The Lancet (www.thelancet.com) is a weekly medical journal, renowned for the publication of high-quality peer-reviewed research and reviews from around the world. In the Podcasts our editors discuss journal highlights, including interviews with authors of key articles to provide context and insight to advancements in medicine and health worldwide.

Share In conversation with... Shun Lu

Sign up to save your podcasts

In conversation with... Shun Lu

In conversation with... Shun Lu